{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:52:10Z","timestamp":1788187930275,"version":"build-2803163510"},"reference-count":39,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>Microelimination targets specific subpopulations and\/or geographic settings for hepatitis C virus (HCV) elimination. This review reports on global HCV microelimination literature published from 2013 to 2020. Data were extracted from publications to report a score based on the four key components defining microelimination. Sustained virologic response (SVR) and treatment initiation proportions were calculated for each manuscript and grouped means of these estimates were compared depending on microelimination score and care setting. A total of 83% of the studies were from high-income settings and mainly included people who use drugs or those incarcerated. Among manuscripts, 18 had \u201clow\u201d microelimination scores, 11 had \u201chigh\u201d scores, and the differences in mean proportion who initiated treatment and achieved SVR between low and high score groups were statistically significant. Microelimination can be a useful complementary strategy for driving engagement in HCV treatment and cure. Our analysis suggests that adhering to more of the core microelimination components can improve outcomes. This study is registered with Prospero, registration identification: CRD42020175211.<\/jats:p>","DOI":"10.1055\/a-1777-6112","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:23:10Z","timestamp":1645471390000},"page":"159-172","source":"Crossref","is-referenced-by-count":37,"title":["A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination"],"prefix":"10.1055","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-2299","authenticated-orcid":false,"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"Barcelona Institute for Global Health (ISGlobal), Hospital Cl\u00ednic de Barcelona, Spain"},{"name":"Faculty of Medicine, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila A.","family":"Picchio","sequence":"additional","affiliation":[{"name":"Barcelona Institute for Global Health (ISGlobal), Hospital Cl\u00ednic de Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Byrne","sequence":"additional","affiliation":[{"name":"Division of Molecular and Clinical Medicine, University of Dundee School of Medicine, Ninewells Hospital, Dundee, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Crespo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospital Marques de Valdecilla. Research Institute Valdecilla-IDIVAL, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Colombo","sequence":"additional","affiliation":[{"name":"General Medicine & Liver Center, San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham S.","family":"Cooke","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Faculty of Medicine, Imperial College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Dore","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Grebely","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Ward","sequence":"additional","affiliation":[{"name":"Coalition for Global Hepatitis Elimination, The Task Force for Global Health, Atlanta, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[{"name":"Division of Molecular and Clinical Medicine, University of Dundee School of Medicine, Ninewells Hospital, Dundee, United Kingdom"},{"name":"Department of Gastroenterology, Ninewells Hospital & Medical School, Dundee, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/liv.14779","article-title":"Progress towards hepatitis C virus elimination in high-income countries: an updated analysis","volume":"41","author":"I Gamkrelidze","year":"2021","journal-title":"Liver Int"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","article-title":"Impact of COVID-19 on global HCV elimination efforts","volume":"74","author":"S Blach","year":"2021","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41591-019-0706-x","article-title":"Global elimination of hepatitis C virus by 2030: why not?","volume":"26","author":"G Dore","year":"2020","journal-title":"Nat Med"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S2468-1253(20)30010-8","article-title":"Global hepatitis C elimination: an investment framework","volume":"5","author":"A Pedrana","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission","volume":"4","author":"G S Cooke","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jhep.2017.06.033","article-title":"Micro-elimination - a path to global elimination of hepatitis C","volume":"67","author":"J V Lazarus","year":"2017","journal-title":"J Hepatol"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-0038-1666841","article-title":"The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations","volume":"38","author":"J V Lazarus","year":"2018","journal-title":"Semin Liver Dis"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/joim.12972","article-title":"We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade","volume":"286","author":"J V Lazarus","year":"2019","journal-title":"J Intern Med"},{"issue":"09","key":"ref13","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2468-1253(19)30201-8","article-title":"Access to hepatitis C care for people who inject drugs and people in prisons","volume":"4","author":"E Oru","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1473-3099(18)30469-9","article-title":"Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis","volume":"18","author":"J Stone","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"L Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12954-018-0269-z","article-title":"Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective","volume":"15","author":"D Crowley","year":"2018","journal-title":"Harm Reduct J"},{"issue":"07","key":"ref17","first-page":"550","article-title":"The contribution of telemedicine to hepatitis C elimination in a correctional facility","volume":"111","author":"G Jim\u00e9nez Gal\u00e1n","year":"2019","journal-title":"Rev Esp Enferm Dig"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/diagnostics11050877","article-title":"Hepatitis C micro-elimination beyond prison walls: navigator-assisted test-and-treat strategy for subjects serving non-custodial sentences","volume":"11","author":"J Cabezas","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"103031","DOI":"10.1016\/j.drugpo.2020.103031","article-title":"Telemedicine efficiently improves access to hepatitis C management to achieve HCV elimination in the penitentiary setting","volume":"88","author":"A Cuadrado","year":"2021","journal-title":"Int J Drug Policy"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"102608","DOI":"10.1016\/j.drugpo.2019.102608","article-title":"Time matters: point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England","volume":"75","author":"Z Mohamed","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"05","key":"ref21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S2468-1253(20)30365-4","article-title":"Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework","volume":"6","author":"M J Akiyama","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/hae.13829","article-title":"Elimination of hepatitis C virus infection in patients with haemophilia in Belgium: a single-centre experience","volume":"25","author":"L Fransen","year":"2019","journal-title":"Haemophilia"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.10.023","article-title":"Progression to hepatitis C virus micro-elimination in people living with HIV in Spain","author":"A Rivero-Juarez","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1002\/hsr2.191","article-title":"Toward microelimination of hepatitis C and HIV coinfection in NHS Tayside, Scotland: Real-world outcomes","volume":"3","author":"C Byrne","year":"2020","journal-title":"Health Sci Rep"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.drugpo.2017.05.019","article-title":"Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs","volume":"47","author":"J Grebely","year":"2017","journal-title":"Int J Drug Policy"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-0040-1708812","article-title":"Hepatitis C virus treatment in children: a challenge for hepatitis C virus elimination","volume":"40","author":"M H El-Sayed","year":"2020","journal-title":"Semin Liver Dis"},{"issue":"06","key":"ref29","first-page":"10","article-title":"Implementing a comprehensive HCV clinic within an HIV clinic: a model of care for HCV micro elimination","volume":"14","author":"C Risk","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"102734","DOI":"10.1016\/j.drugpo.2020.102734","article-title":"Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain","volume":"80","author":"V Saludes","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","article-title":"Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis","volume":"9","author":"E Oru","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1055\/s-0040-1713657","article-title":"Simplification of care for chronic hepatitis C virus infection","volume":"40","author":"J M Pawlotsky","year":"2020","journal-title":"Semin Liver Dis"},{"issue":"03","key":"ref33","first-page":"119","article-title":"Hepatitis C reflex testing in Spain in 2019: A story of success","volume":"39","author":"J Crespo","year":"2021","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/cid\/ciz985","article-title":"Moving towards hepatitis C microelimination among people living with human immunodeficiency virus in australia: the CEASE study","volume":"71","author":"M Martinello","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.drugpo.2019.07.002","article-title":"An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study","volume":"72","author":"M Alavi","year":"2019","journal-title":"Int J Drug Policy"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.drugpo.2019.02.012","article-title":"Quantitative evaluation of an integrative nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia","volume":"72","author":"B L Harney","year":"2019","journal-title":"Int J Drug Pol"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMsr1912628","article-title":"Screening and treatment program to eliminate hepatitis C in Egypt","volume":"382","author":"I Waked","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S2468-1253(18)30139-0","article-title":"An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project","volume":"3","author":"G Shiha","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1478-3231.2006.01290.x","article-title":"High prevalence of infection with a single hepatitis C virus genotype in a small rural community of Argentina","volume":"26","author":"G R Picchio","year":"2006","journal-title":"Liver Int"},{"issue":"S 01","key":"ref40","doi-asserted-by":"crossref","first-page":"100577","DOI":"10.1016\/j.aohep.2021.100577","article-title":"Twenty-year follow-up of an outbreak of hepatitis C in a small rural town of Argentina: the O'Brien project","volume":"27","author":"F G Villamil","year":"2022","journal-title":"Ann Hepatol"},{"issue":"02","key":"ref41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.idc.2018.02.003","article-title":"Strategies to reduce hepatitis C Virus reinfection in people who inject drugs","volume":"32","author":"M Martinello","year":"2018","journal-title":"Infect Dis Clin North Am"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12889-020-8294-8","article-title":"High prevalence of human immunodeficiency virus, hepatitis B and C viral infections among people who inject drugs: a potential stumbling block in the control of HIV and viral hepatitis in Tanzania","volume":"20","author":"R H Kawambwa","year":"2020","journal-title":"BMC Public Health"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S2215-0366(15)00357-0","article-title":"Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis","volume":"3","author":"E Hughes","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1176\/appi.ajp.160.1.172","article-title":"Prevalence of hepatitis C among psychiatric patients in the public sector","volume":"160","author":"S H Dinwiddie","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"07","key":"ref45","first-page":"550","article-title":"Prevalence of hepatitis C in patients with non-affective psychotic disorders","volume":"112","author":"A Cuadrado","year":"2020","journal-title":"Rev Esp Enferm Dig"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1777-6112.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T07:18:18Z","timestamp":1660115898000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1777-6112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":39,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2022,6,23]]},"published-print":{"date-parts":[[2022,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1777-6112","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2,21]]},"published":{"date-parts":[[2022,2,21]]}}}